

## **CURRICULUM VITAE**

**February 2014**

**Ray L. Watts, MD**

### **BUSINESS ADDRESSES**

University of Alabama at Birmingham  
1720 2<sup>nd</sup> Avenue South  
Administration Building 1070  
Birmingham, Alabama 35294  
Telephone: 205-934-4636  
Fax: 205-975-8505  
Email: rlwatts@uab.edu

### **PRESENT FACULTY/PROFESSIONAL/LEADERSHIP POSITIONS**

2/13-Present	President, University of Alabama at Birmingham
9/10-2/13	Sr. Vice President & Dean, UAB School of Medicine
9/10-2/13	James C. Lee Endowed Chair
7/03-Present	Professor of Neurology
9/06-Present	Sr. Scientist, UAB Comprehensive Neuroscience Center
3/11-Present	Sr. Scientist, Center for Exercise Medicine

### **EXECUTIVE LEADERSHIP POSITIONS/RESPONSIBILITIES**

1. President, University of Alabama Health Services Foundation (Multi-specialty group practice of the over 1000 physicians who comprise the full-time clinical faculty of the UAB School of Medicine; over \$400 million in annual revenue and net assets of over \$500 million). [10/05-9/10]
2. Interim CEO, University of Alabama at Birmingham Health System (Governing entity for UAB Hospital, UAB Highlands Hospital, Callahan Eye Foundation Hospital, The Kirklin Clinic and UAB Satellite Clinics). [1/08-9/08]
3. Board of Directors, University of Alabama Health Services Foundation (UAHSF) [10/05-2/13]
4. Board of Directors, UAB Health System [10/05-Present]
5. Joint Operating Leadership Group, UAB Medical Center, 2005-Present (comprised of the Senior VP/Dean of the UAB School of Medicine, CEO of the UAB Health System, and President of the UAHSF) [10/05-2/13]
6. Chair, Executive Committee, UAHSF [10/05-9/10]
7. Executive Committee, UAB Health System [10/05-Present]

8. Chair, Medical Leadership Committee, UAB Health System [10/05-9/10]
9. Chair, School of Medicine Executive Committee [9/10-2/13]
10. Vice Chair, Board of Directors, UAB Health System [9/10-2/13]
11. Chair, Finance Committee, UAB Health System [9/10-2/13]
12. Chair, UAB Health System Board [2/13-Present]
13. Member, Executive Committee & Board of Directors, Birmingham Business Alliance [3/13-Present}

### **PREVIOUS FACULTY/PROFESSIONAL POSITIONS**

- 7/86-8/92 Assistant Professor, Department of Neurology, Emory University
- 7/86-6/03 Director, Movement Disorders Program, Emory University
- 7/86-6/03 Attending Neurologist, Emory University Affiliated Hospitals, the Emory Clinic and Wesley Woods Geriatric Hospital
- 7/87-6/03 Affiliate Scientist, Division of Neurobiology, Yerkes Regional Primate Research Center, Emory University
- 9/87-6/03 Medical Director, American Parkinson Disease Association (APDA) Information and Referral Center, Emory University
- 9/92-9/98 Associate Professor, Department of Neurology, Emory University
- 1990-2003 Co-Director, APDA Advanced Center for Parkinson Research at Emory University
- 9/98-6/03 Professor, Department of Neurology, Emory University
- 9/98-6/03 Vice-Chairman, Department of Neurology, Emory University
- 9/98-6/03 Chief, Neurology Service, Emory University Hospital
- 9/98-6/03 Associate Section Head, Section of Neurology, The Emory Clinic, Inc.
- 9/98-6/03 Chief, Neurology Service, Wesley Woods Geriatric Center
- 9/00-6/03 A.Worley Brown Endowed Professor in Neurology, Emory University
- 9/01-6/03 Director, Clinical Trials Office, School of Medicine, Emory University
- 2/02-6/03 Member, Executive Committee, Institutional Review Board, Emory University
- 7/03-9/10 Professor and Chairman, Department of Neurology, University of Alabama at Birmingham (UAB)
- 7/03-9/10 Chief, Neurology Service, UAB Hospital
- 12/03-9/10 John N. Whitaker Endowed Chair in Neurology, University of Alabama at Birmingham
- 01/05-10/05 President-elect, University of Alabama Health Services Foundation, University of Alabama at Birmingham
- 10/05-1/08, President, University of Alabama Health Services Foundation, University of Alabama at Birmingham
- 09/08-9/10 Alabama at Birmingham
- 01/08-09/08 Interim CEO, UAB Health System

### **EDUCATIONAL BACKGROUND**

School of Engineering, University of Alabama at Birmingham, 1972-76, B.S.E., with Honors (Biomedical and Electrical Engineering)

School of Medicine, Washington University, St. Louis, 1976-80, M.D., with Highest Honors

### **POST GRADUATE TRAINING**

- 1980-81 First Year Medical Resident, Massachusetts General Hospital, Clinical Fellow in Medicine, Harvard Medical School, Boston, MA
- 1981-84 Neurology Resident, Massachusetts General Hospital, Clinical Fellow in Neurology, Harvard Medical School
- 1982-83 Electromyography and Motor Control Fellow, Clinical Neurophysiology Laboratory, Massachusetts General Hospital
- 1982-84 Resident Member, Movement Disorders Clinic, Massachusetts General Hospital (part-time)
- 1983-84 Chief Resident, Neurology, Massachusetts General Hospital
- 1984-86 Medical Staff Fellow, NIMH Laboratory of Neurophysiology, National Institutes of Health, Bethesda, MD. (Motor Control and Movement Disorders)

### **BOARD CERTIFICATION**

American Board of Psychiatry and Neurology (Neurology), November, 1985

### **MEDICAL LICENSURE**

Alabama (active); Georgia (active); Massachusetts (inactive); Washington, D.C. (inactive); Virginia (inactive); Maryland (inactive)

### **HONORS AND AWARDS**

#### Undergraduate

- Student Engineer of the Year for Alabama, 1974-75, Alabama Society of Professional Engineers
- Merit Scholarship, University of Alabama, Birmingham 1972-76
- Omicron Delta Kappa, National Honorary Leadership Society (President, UAB Chapter)
- Phi Kappa Phi, National Honor Society
- Valedictorian, Class of 1976
- Most Outstanding Undergraduate Student, University of Alabama, Birmingham, 1976.
- Dean's Award, School of Engineering, 1976

#### Medical School

- Valedictorian, Class of 1980
- Student Research Fellowship, Summer, 1977 (Neurochemistry)
- Dr. Richard Brookings Medical School Prize for Outstanding Junior Student, 1978-79
- Student Research Fellowship, 1979-1980 (Neurophysiology)
- Alpha Omega Alpha, Medical Honor Society, 1979 (Junior Year Inductee)
- Alpha Omega Alpha Senior Book Award, 1980 (Presented to Valedictorian)
- Dr. Irwin Levy Senior Prize in Neurology and Neurological Surgery, 1980

#### Professional

University of Alabama Medical Alumni Association, 2014 Distinguished Service Award

Research, Teaching and Clinical

Dr. George Cotzias Memorial Research Fellowship Award, American Parkinson Disease Association, "Pathophysiology and Treatment of Experimental Parkinsonism"  
\$150,000, 7/1/89 - 6/30/92

Favorite Neurobiology Professor, Emory University School of Medicine, 1991(chosen by Freshman Medical School class)

"Best Doctor's in America," Woodward and White, 1994-present

Outstanding Neurology Professor, 1998 (Teaching award; chosen by Emory Neurology Residents)

1999 Health Care Hero Award, Physician nominee, sponsored by Atlanta Business Chronicle

A. Worley Brown Endowed Professor in Neurology, Emory University, 2000-2003

"America's Top Doctor's", Castle and Connolly, 2000-present.

"Atlanta's Best Doctors", Atlanta Magazine, 2001-2003

John N. Whitaker Endowed Chair in Neurology, University of Alabama at Birmingham, 2003-2010

"Birmingham's Best Doctors", Birmingham Magazine, 2003-present

Birmingham Business Journal's "Who's Who in Health Care" for 2007

UAB Distinguished Alumni Award, 2007

James C. Lee Endowed Chair (held by the Dean of the School of Medicine, UAB), 2010-Present

Fellow, American Neurological Association, 2013-Present

**RESEARCH GRANT AWARDS**

Biomedical Research Support Grant (Emory University), NIH BRSG SO7 RR05365. "Study of Pathophysiology and the Effects of Treatment in MPTP Parkinsonian Monkeys." P.I.- Ray L. Watts, one-time award of \$15,000 used to purchase laboratory computer; 6/20/86-6/19/88

United Parkinson Foundation Research Grant Award. "Study of Pathophysiology and the Effects of Treatment in MPTP Parkinsonian Monkeys." P.I.- Ray L. Watts; direct costs \$20,000; 1/1/87-12/31/87

NIH RO1 NS24312. "Pathophysiology of MPTP Parkinsonians." P.I.- Ray L. Watts; 75% effort; direct costs \$264,000; 1/1/87-12/31/89

Alzheimer's Disease and Related Disorders Research Grant Award. "Objective Assessment of Parkinsonian Features in Alzheimer's Disease." Co-Investigator: Ray L. Watts, (P.I.- Susan M. Ditter); direct costs \$20,000; 11/1/87-11/30/88

American Parkinson Disease Association Research Grant Award. "Investigation of Surgical Technique in the Treatment of Parkinsonism." Co-Investigator: Ray L. Watts, (P.I.- Roy A. E. Bakay); direct costs \$20,000; 7/1/88-6/30/89

NIH RO1 NS24340. "CNS Grafting for Parkinsonism." Co-Investigator: Ray L. Watts (P.I. - Roy A.E. Bakay); annual total costs \$290,752; 4/1/89-3/31/92

Emory University Research Committee Research Grant, Emory University, "Assessment of Changes of Motor Performance Related to Normal Aging and Early Parkinson Disease." Co-P.I., Ray L. Watts (Co-P.I., Alan Freeman); \$10,000; 7/90-6/91

VA Merit Award #0001. "Safety and Efficacy of Neural Grafting for the Treatment of Parkinson Disease"; Co-Investigator - Ray L. Watts (P.I. - Roy A.E. Bakay) \$149,000, 4/1/91-3/31/94

VA Merit Award #5747-4. "Cytoskeletal Pathology in Alzheimer's Disease - Parkinson's Disease Features in Alzheimer's Disease Patients." Co-Investigator - Ray L. Watts (P.I. - S.S. Mirra); \$85,420/year; 10/1/90-9/30/95

Hoffman-LaRoche, Inc., Protocol NN14104-ROADS/Parkinson Study Group. "Determination of the Dose Response and Plasma Concentration Response of Lazabemide (Ro 19-6327) in Delaying the Time until Treatment with Levodopa/Carbidopa is Required in Parkinson's Disease Patients" (ROADS - Ro 19-6327 Assessment and Dose-finding Study). P.I.-Ray L. Watts; \$128,620/yr; 3/18/92 - 3/17/93

NIH U10N531321-01. The Parkinson's Institute (subcontract at Emory). "Detecting Preclinical Parkinsonism in Humans." Co-Inv., Ray L. Watts; \$276,712/yr total, \$36,396/yr subcontract only; 7/1/92 - 6/30/95

American Parkinson Disease Association Research Grant Award. "Analysis of New Electrophysiological Techniques for Preclinical and Early Detection of Human Parkinsonism." P.I.: Ray L. Watts. \$24,975/yr; 9/1/93-8/30/94

Foundation for Physical Therapy Grant. "Early Electrophysiologic Detection of Human Parkinsonism." Co-Inv. & Faculty Sponsor: Ray L. Watts (P.I.: Claire L. Maier, Neuroscience Ph.D. student) \$5,000; 9/1/93-8/31/94

NIH 1U10NS31321-01, "Twin Studies in Parkinson Disease." Emory Investigator: Ray L. Watts (P.I.: Caroline M. Tanner) \$5,000/year, 7/1/92-3/31/95

Cytotherapeutics, Inc. "Cellular Transplants in Experimental Parkinsonism." P.I.: Ray L. Watts (Co-P.I.: Roy A.E. Bakay); \$137,012, 1/92-12/95

The Upjohn Company, Protocol M/2730/0001. "Double-blind, Placebo-controlled, Parallel-group Comparison to Assess the Safety, Tolerance, and Efficacy of Pramipexole in Early Parkinson's Disease (Part I) and to Assess Long Term Safety with Open-label Pramipexole (Part II)" (Pramipexole Study)." P.I.: Ray L. Watts; \$56,400/yr; 8/20/93 - 12/31/97

Hoffman-LaRoche, Inc, Protocol NZ14653. "A Dose-Response Efficacy Study of Tolcapone (Ro 40-7592) Compared with Placebo in Parkinson's Disease Patients Who are Stable Responders to

Levodopa/Carbidopa (Sinemet)" (Tolcapone Study) P.I.: Ray L. Watts; \$123,533, 2/14/94-12/31/97 (Extension)

Ross Products Division, Abbott Laboratories. "The Use of a Very Low Protein Supplement in a Parkinson's Disease Population." P.I.: Ray L. Watts, M.D.; \$50,000, 8/26/94-8/25/95.

Eli Lilly & Co. "Effects of m5 Muscarinic & AMPA Compounds on Motor Performance in Hemi-Parkinsonian Monkeys." P.I.s: Allan I Levey, Ray L. Watts; \$68,700; 9/15/94 - 12/31/95

NIH RO1-NS-24340. "CNS Grafting for Parkinsonism." Co-Inv: Ray L. Watts (P.I.: Roy A.E. Bakay); direct costs - \$151,422/yr.; 4/1/93-3/31/99

NIH P30 AG 10130. Alzheimer's Disease Center, (P.I. - Suzanne S. Mirra). Co-Investigator, Ray L. Watts: Clinical Core; \$181,430/yr; 9/30/91 - 6/30/99

Duke University Medical Center (Deane Laboratory). Parkinson disease genetic collaborative study. Emory P.I.: Ray L. Watts, M.D. \$120,000, 1/1/96 – 12/31/01

Athena Neurosciences, Inc. "A Double-Blind, Placebo-Controlled, Single Dose, Dose-finding Safety, Tolerability and Preliminary Efficacy Study of BotB (Botulinum Toxin Type B) in Patients with Idiopathic Cervical Dystonia." Co-Investigator: Ray L. Watts, M.D. (P.I.: Alan Freeman, M.D.); \$54,160, 6/30/97 – 12/31/00

Theracell, Inc. "Intrastriatal implantation of retinal pigmented epithelial cells in parkinsonian monkeys: a pilot study" (Emory/Theracell 001). P.I.: Ray L. Watts, M.D.; \$69,842, 11/1/96-11/7/97

Theracell, Inc. "Intrastriatal implantation of retinal pigmented epithelial cells in parkinsonian monkeys: a pivotal study" (Emory/Theracell 002). P.I.: Ray L. Watts, M.D.; \$513,809, 1/1/97-06/30/00

Theracell, Inc. "Assessment of dopamine transporter in retinal pigmented epithelial (RPE) cells and immunological consequences of intrastriatal implantation of xenogeneic (RPE) cells in hemiparkinsonian rats" (Emory/Theracell 003). P.I.: Ray L. Watts, M.D.; \$19,628, 1/1/97 - 5/1/97

Pharmacia & Upjohn. The effect of pramipexole on depressive symptoms in Parkinson's disease patients. P.I.: Ray L. Watts, M.D.; \$66,300, 4/1/99 – 3/31/00

NIH R01 NS36711/Boston University School of Medicine. Genetic linkage study in Parkinson's disease. Emory P.I.: Ray L. Watts, M.D.; Project P.I.: R.H. Myers, PhD; total project costs \$2,999,535; 7/1/97 – 6/30/02

Novartis Pharmaceuticals. A prospective, randomized, parallel-group, double-blind, placebo-controlled, multi-center study to evaluate the short-term and safety of Entacapone administered together with levodopa in subjects with Parkinson' disease without motor fluctuations. Emory P.I.: Ray L. Watts, M.D.; \$83,013; 10/1/97 – 6/30/00

Amgen, Inc. Randomized, double-blind, placebo-controlled, 6-month safety, efficacy, and neuroimaging trial of the neuroimmunophilin AMG-474-000 in the treatment of patients with Parkinson's disease (Protocol: 2000105). P.I. Ray L. Watts, MD; \$58,000; 9/1/00-12/31/01

SmithKline Beecham, Inc. A double-blind, multicentre, flexible dose, l-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson's disease (Requip) P.I.: Ray L. Watts, M.D.; \$1,078,364, 11/1/97 - 12/31/01 (blinded phase); \$31,127, 10/1/01-9/30/04 (open-label phase)

Diacrin, Inc. A double-blind, randomized, controlled multicenter clinical trial of the safety and efficacy of transplanted fetal porcine cells in patients with Parkinson's disease. Emory P.I.: Ray L. Watts, M.D.; \$1,253,413, 12/1/97 – 2/10/02

SmithKline Beecham Pharmaceuticals. Double-blind, placebo-controlled, parallel group study of ropinirole vs. placebo in Restless Leg Syndrome. P.I.: Ray L. Watts, M.D.; \$334,880, 8/1/98 – 12/31/01

NIH R01NS34796/Columbia University/Parkinson Study Group (PSG), a multi-center study, "Earlier vs. later levodopa in Parkinson's disease" (The ELLDOPA Study), Emory P.I.: Ray L. Watts, M.D. (P.I. Stanley Fahn, M.D.), \$89,760, 4/1/99-3/31/02

NIH R01NS36714/University of California – San Diego. Effects of CoEnzyme Q10 in early Parkinson's disease. Emory P.I.: Ray L. Watts, M.D, (P.I. Cliff Shults, MD): \$90,040, 4/1/99 – 3/31/02

NIH 1R44NS39211/Titan Pharmaceuticals, Inc. Stereotactic intrastriatal transplantation of Spheramine™ in advanced Parkinson's disease patients: a pilot study of tolerability and efficacy. P.I.: Ray L. Watts, M.D., \$640,692, 1/25/00-7/24/02

Schwarz Biosciences, Inc. A multicenter, multinational, phase III, randomized, double blind, placebo controlled trial of the efficacy and safety of the rotigotine CDS patch in subjects with early stage idiopathic Parkinson's disease. P.I.: Ray L. Watts, M.D; \$78,780; 3/1/03-3/31/04.

Merck KgaA. A multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to investigate the anti-dyskinetic efficacy and safety of Sarizotan in Parkinson patients with L-dopa induced dyskinesia (EMR 62 225-006). P.I.: Ray L. Watts, M.D; \$62,400; 7/1/02-6/30/04

Kyowa Pharmaceutical, Inc. A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/day KW-6002 as Treatment for Parkinson's Disease in Patients with Motor Response Complication on Levodopa/Carbidopa Therapy. P.I.: Ray L. Watts, M.D; \$66,000; 5/1/02-4/30/04

Pharmacia/Pfizer Pharmaceuticals. A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumaniprole versus

Placebo in Patients with Early Parkinson's Disease. P.I.: Ray L. Watts, MD; \$111,332; 07/01/03-08/01/04

Kyowa Pharmaceuticals. A long-term, open-label safety study with oral 20 or 40mg/d doses of KW-6002 (Istradefylline) as treatment of Parkinson's disease in patients with motor response complications on levodopa therapy. PI: Ray L. Watts, MD; \$33,750; 01/01/05-12/31/06

Merck KgaA. Open-label, multicenter, multinational, phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg. Bid in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY-O). PI: Ray L. Watts, MD and Natividad Stover, MD; \$24,907; 05/02/05-05/31/08

Schwarz Biosciences. A multicenter, multinational, phase 3B, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease. PI: Ray L. Watts, MD; \$52,020; 05/05/05-06/30/08

Advanced Neuromodulation Systems, Inc. Clinical evaluation of the ANS Totally Implantable Deep Brain Stimulation System for the suppression of tremor in the upper extremities of patients with essential tremor. PI: Ray L. Watts and Barton Guthrie, MD; \$11,892; 06/22/05-06/22/10

Kyowa Pharmaceutical, Inc., A phase II, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the efficacy and safety of 40mg/day KW-6002 (Istradefylline) as monotherapy in subjects with Parkinson's disease. PI: Ray L. Watts; \$26,440; 07/15/05-01/14/07

Teva Neuroscience. Multicenter, double-blind, randomized start, placebo-controlled, parallel-group study to assess Rasagiline as a disease modifying therapy in early Parkinson's disease subjects (ADAGIO). PI: Ray L. Watts, \$20,168; 12/20/05-06/19/08

Berlex Laboratories, Inc., Study of the safety, tolerability and efficacy of Spheramine® implanted bilaterally into the postcommissural putamen of patients with advanced Parkinson's disease. PI: Ray L. Watts, MD; \$594,140, 12/02/03 – 09/30/12

Kyowa Pharmaceutical, Inc., An Open-Label Multicenter Study of the Continued Safety of istradefylline (KW-6002) in Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With istradefylline. PI: Ray L. Watts, MD, \$13,500, 03/10/06 – 01/12/09

NIH1U10 NS44547 / UAB Parkinson's Disease Neuroprotection Clinical Trial Center. P.I: Ray L. Watts, M.D.; \$290,969, 12/01/07 – 11/30/2012

Investigator Initiated (funded by GlaxoSmithKline), The occurrence of cardiac valve regurgitation in Parkinson Disease patients treated with ropinirole. Co-investigator: Ray L. Watts; \$79,000, 01/24/06 – 05/31/09.

Ceregene, Inc., A multicenter, randomized, double-blind, sham surgery-controlled study of CERE-120 (Adeno-associated virus serotype 2[AAV2]-neurturin [NTN]) to assess the efficacy and safety of



bilateral intraputaminial (IPu) delivery in subjects with idiopathic Parkinson's disease. P.I.: Ray L. Watts, M.D.; \$201,680, 03/14/07-03/13/10

Alseres Pharmaceuticals, Inc., 123 I-ALTROPANE® reference image acquisition in subjects with diagnostically uncertain tremor (AIM). P.I.: Ray L. Watts, M.D.; \$29,890, 12/10/07 – 06/30/09

Ceregene, Inc., Extended observation study to assess the safety and efficacy of Idiopathic Parkinson's Disease patients treated with CERE-120 (Adeno-Associated Virus Serotype 2[AAV2]-Neurturin[NTN]). P.I.: Ray L. Watts, M.D.; \$298,778, 03/14/08 – 3/13/20

Chelsea Therapeutics, Inc., Droxidopa-302, A multi-center, double-blind, randomized, placebo-controlled, parallel-group withdrawal-design study to assess the clinical effect of droxidopa in subjects with primary autonomic failure, dopamine beta hydroxylase deficiency or non-diabetic neuropathy and symptomatic neurogenic orthostatic hypotension. P.I.: Ray L. Watts, M.D.; \$76,325, 09/20/08 – 09/20/12

Chelsea Therapeutics, Inc., A multi-center, open-label study with a two week randomized, placebo-controlled withdrawal period to assess the long-term safety and clinical benefit to droxidopa in subjects with primary autonomic failures, dopamine beta hydroxylase deficiency or non-diabetic neuropathy and symptomatic neurogenic orthostatic hypotension. P.I.: Ray L. Watts, M.D.; \$37,164, 09/20/08 – 09/20/12

Alzheimer's Disease Cooperative Study/ National Institute on Aging (ADCS/NIA) CTA12-UAB (NGF) M-00ADCS / Ceregene, Inc, A double-blind, placebo-controlled (sham surgery), randomized, multicenter study evaluating CERE-110 gene delivery in subjects with mild to moderate Alzheimer's disease. P.I.: Ray L. Watts, M.D.; \$178,273, 06/11/09 – 06/10/12

Teva Pharmaceutical Industries LTD, An open-label, multi-center, follow-up study designed to evaluate the long-term effects of rasagiline in Parkinson's disease subjects who participated in the ADAGIO Study. Co-P/I.: Ray L. Watts, M.D.; \$24,000, 09/22/2009-12/31/2012

Ceregene, Inc., A phase 1 / 2 trial assessing the safety and efficacy of bilateral intraputaminial and intranigral administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in subjects with idiopathic Parkinson's disease, P.I.: Ray L. Watts, M.D. \$500,343, 06/03/2010-06/02/2015

### **CENTER GRANTS**

AMERICAN PARKINSON DISEASE ASSOCIATION INFORMATION AND REFERRAL CENTER GRANT. Medical Director, Ray L. Watts. M.D.; direct costs \$30,000 per year (renewed annually); 9/1/87- 6/30/03

CENTER FOR AGE-RELATED NEUROLOGICAL DISEASES GRANT; P.I., Ray L. Watts, MD; \$450,000; Anonymous Private Foundation, 1988-1991

ADVANCED CENTER FOR PARKINSON RESEARCH GRANT, American Parkinson Disease Association, Emory University School of Medicine, Co-P.I., Ray L. Watts (P.I., Mahlon R. DeLong), \$105,000/year, 1990- 2003 (renewable annually)

PARKINSON DISEASE CENTER CAMPAIGN, Emory University School of Medicine, Ray L. Watts, MD, Chair;1999-2003; \$10,000,000 goal reached

ALZHEIMER'S DISEASE RESEARCH CENTER GRANT: CLINICAL CORE. NIH/NIA; University of Alabama at Birmingham; Co-PI: Ray L. Watts, MD; \$1,901,558; 04/04/04 – 03/31/09

ADVANCED CENTER FOR PARKINSON RESEARCH GRANT, American Parkinson Disease Association, University of Alabama at Birmingham, Co-PI, Ray L. Watts (PI, David G. Standaert), \$130,000/year, 2006-present (renewable annually)

### **COMMITTEE ASSIGNMENTS**

1. Emory University School of Medicine Long-Range Planning Committee, 1988-90
2. Emory University School of Medicine Curriculum Committee/Subcommittee on Computers and Technology, 1990-91
3. American Academy of Neurology Education Committee/Medical Student Essay Award Subcommittee, 1988-1991
4. Medical Association of Atlanta Communications Committee, 1989-92
5. At-Large Member, Executive Committee, The Emory Clinic, 1991-1993 (changed from partnership to non-profit corporation 1993)
6. Organizing Committee - Parkinson Study Group/Movement Disorders Society 6th Annual Symposium on the Etiology, Pathogenesis, and Prevention of Parkinson's Disease, Toronto, Canada, 1992; 7th Annual Symposium on the Etiology, Pathogenesis, and Prevention of Parkinson's Disease, Boston, MA, 1993
7. Clinical Operations Committee, Department of Neurology, Emory University, 1992-2003; Chair, 1998-2003
8. International Scientific Program Committee, 3rd International Congress of Movement Disorders, Orlando, FL, November 1994
9. Finance Team, The Emory Clinic Project 2000; Board of Directors, The Emory Clinic, 1995
10. Finance Committee, The Emory Clinic, Inc., 1996-1998
11. Leadership Council, The Emory Clinic, Inc. - 1996-2003
12. Academic Enrichment Fund Subcommittee, Finance Committee, The Emory Clinic, Inc. 1996-97
13. Department of Rehabilitation Medicine Chair Search Committee, Emory University School of Medicine, 1996-1997
14. Nominating Committee, Movement Disorders Section, American Academy of Neurology, 1996-97
15. Executive Committee, Department of Neurology, Emory University, 1998-2003
16. Professional Services Committee, Emory University Hospital, 1998-2003
17. Clinical Operations Committee, The Emory Clinic, 1998-2000
18. Medical Leadership Committee, Wesley Woods Center, 1998-2003

19. Executive Committee, Center for Geriatrics, Emory University, 5/99-6/03
20. Leadership Committee for Assessment of Strategy and Reorganization, Emory Healthcare, 6/99-9/99
21. Clinical Research Decision Team, Emory Healthcare, 2001-2003
22. Research Advisory Committee, Emory University School of Medicine, 2001-2003
23. Medical Executive Committee, UAB Hospital and Health System, 2003 – Present
24. Executive Committee, UAB School of Medicine, 2003 – Present, Chair, 2010-Present
25. University of Alabama Health Services Foundation (UAHSF) Advisory Committee, 2003 – 2005
26. Medical Leadership Committee, UAB Health System, 2003 – Present; Chair, 2005-2010
27. UAHSF Investment Committee, 2003 – 2010
28. Chair, UAB Department of Psychiatry Chair Search Committee, 2004-2005
29. UAHSF Executive Committee 2005-Present
30. UAHSF General Endowment Fund Committee, 2005- 2010
31. UAHSF Administrative Services Committee, 2005- 2010
32. UAB Health System, Compensation Committee, 2005- Present
33. UAB Health System, Executive Committee, 2005-Present
34. UAB Health System, Finance Committee, 2005-Present, Chair, 2010-Present
35. UAB Health System, Audit and Compliance Committee, 2005-Present
36. Steering Committee and Founding Member, UAB Comprehensive Neuroscience Center, 2006-Present
37. Finance Committee, American Neurological Association, 2009-Present
38. Finance Committee, Alabama Symphony Orchestra, 2009-Present

### **PROFESSIONAL AFFILIATIONS**

American Neurological Association; American Academy of Neurology; Society for Neuroscience; Alpha Omega Alpha; Movement Disorders Society; International Brain Research Organization; Medical Association of State of Alabama; Alabama Academy of Neurology

### **ADVISORY BOARDS/DIRECTORSHIPS/COMMUNITY SERVICE**

Board of Directors, Community Foundation of Greater Birmingham, 2012-Present  
Board of Directors, Alabama Symphony Orchestra (ASO), 2009-Present; Chair, *Doctors for the Alabama Symphony Orchestra* Giving Society, 2009-2013  
Corporate Advisory Board, Alys Stephens Center (ASC) for Performing Arts at UAB, 2009-Present;  
Co-Chair, Medical Arts Alliance for the ASC Performing Arts Center, 2009-Present  
Tocqueville Society Cabinet, United Way of Central Alabama, 2009-2011  
Board of Directors, UAB Research Foundation, 2009-Present  
Medical Advisory Board, International Essential Tremor Foundation, 2007-Present  
International Advisory Board, Parkinson Disease Therapeutics and Cell Therapy, Bayer Schering Pharma, 2007-2009  
Data Safety Monitoring Board, Solstice Pharmaceuticals, “Myobloc for Sialorrhea” Clinical Development Program, 2007-2009  
International Advisory Board, Parkinson Disease Therapeutics, Schwarz Pharma, 2002-2008

Data and Safety Monitoring Board, Multicenter Cooperative Study on “A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson’s Disease”, CSP # 468, U.S. Department of Veterans Affairs, 2002-2003

Founding Member, Tremor Research Group (National), 2001-present; President, 2001-2004

Global Advisory Board, Parkinson Disease Therapeutics, Pharmacia Inc, 2001- 2003

Global Advisory Board, Parkinson Disease Therapeutics, GlaxoSmithKline, 2000 - 2008

Medical and Scientific Advisory Board, American Parkinson Disease Association, New York, NY, 1992-present

Data & Safety Monitoring Committee, Guilford Pharmaceuticals GPI 1485 Clinical Trial Protocol 0501-0201, 2003 – 2005

Peer Review Board for Research Grants, Benign Essential Blepharospasm Research Foundation, Inc. 1990-1994

Elected At-Large Member, Board of Directors, The Emory Clinic, Inc., 1993-1996.

Medical Advisor, Board of Directors, American Parkinson Disease Association, Atlanta Chapter, Atlanta, GA, 1987-2003

### **EDITORIAL BOARDS**

Movement Disorders Journal, 1990-1994; Neurology Chronicle Journal, 1992-1994

### **REVIEWER**

Neurology, Annals of Neurology, New England Journal of Medicine, Movement Disorders, Clinical Neurophysiology, Clinical Neuropharmacology, Trends in Neurosciences, The Gerontologist, NIH Neurology A Study Section and General Clinical Research Center (GCRC) Study Sections, United Parkinson Foundation Research Grant Applications, University Research Committee Grant Applications/Emory University, Veterans Affairs Research Grants. Abstract Review Committee, Movement Disorders Section, American Academy of Neurology Annual Scientific Meetings, 1992, 1994, 1995

### **TEACHING ASSIGNMENTS**

Emory University:

1. Lecturer/Small Group Discussion Leader: Courses taught include Neurobiology (15+ years),
2. Physiology (6+ years), Biology of Motor Control I & II (8+ years), Pathology (11+ years), Introduction to Clinical Methods (10+ years), Neurological Pathophysiology (5+ years), Neurology Clerkship and Electives (15+ years)
3. Coordinator - Neurology Senior Clerkship Course and Electives, 1987-1989
4. Advisor/Mentor: Ph.D. Advisor, Allen Mandir, M.D., Ph.D., Neuroscience, 1989; Claire L. Maier, Ph.D., Neuroscience, 1999. Mentor for numerous medical students, graduate students, Neurology residents, and postdoctoral fellows (research and clinical training)
5. Ph.D. Dissertation Committee Member, John H. Lawrence, Ph.D., successful defense, May 1994

6. Grand Rounds/Teaching Conferences: Invited Speaker in the Departments of Neurology, Medicine, Neurosurgery, Rehabilitation Medicine, and Psychiatry (several times/year)
7. Faculty Coordinator, Neurology Grand Rounds - 1986-88
8. Curriculum Committee/Subcommittee on Computers and Technology, EUSM, 1990-91
9. Mini-Medical School/Evening at Emory Continuing Education: Lecture on “The Brain and
10. Nervous System and Neurological Disorders” (>6 years)
11. CME Programs - Course Director, Parkinson Disease/Movement Disorders Symposia (annual); Lecturer, Neurology and Neurosurgery Update (annual), Internal Medicine Board Review Course (annual)

University of Alabama at Birmingham:

1. CME Programs - Course Director, Parkinson Disease/Movement Disorders Symposia (annual)
2. Grand Rounds/Seminars/Teaching Conferences - Invited Speaker in the Departments of Neurology, Neurobiology, and Cell Biology
3. Medical Neuroscience Course (First year medical students) – Lecturer/Presenter
4. Annual “Update in Neurology CME Program” – UAB Department of Neurology and Alabama Academy of Neurology (2004, 2005, 2006, 2007)

Community/Lay and Professional Organizations (Local, National, and International):

1. Lay Organizations: Medical Director, American Parkinson Disease Association (APDA) Information and Referral Center at Emory University (serving Southeastern USA) and Medical Advisor, APDA Atlanta Chapter and Support Group (11+ years) - Guest speaker at monthly Education and Support Group Meetings; Keynote Speaker, American Parkinson Disease Association National Conferences (8 times over 10+ years); Member, APDA National Scientific Advisory Board (1992-2003); Keynote Speaker - Parkinson Disease Support Groups throughout USA
2. Professional Organizations: American Academy of Neurology: Education Committee/Medical Student Essay Award Subcommittee, 1988-1991; Annual Scientific Meeting Abstract Review Committee, 1992-1995; Program Director, 11th Annual Benign Essential Blepharospasm Research Foundation International Symposium, 1993, Atlanta, GA; Scientific Program Committee, 3rd International Congress of Movement Disorders, Orlando, FL, 1994; Organizing Committee, Movement Disorders Society Annual Symposium on the “Etiology, Pathogenesis and Prevention of Parkinson’s Disease,” Toronto, Canada, 1992 and Boston, MA, 1993; Organizing Committee and Lecturer, International Tremor Foundation Movement Disorders Review Course, 1 Day CME Program, 1997, Chicago, New York, Philadelphia, Atlanta, Los Angeles, San Francisco; Guest Speaker, Annual Scientific Sessions of the Georgia Neurological Society, Alabama Academy of Neurology, South Carolina Neurological Society, et al.; Communications Committee, Medical Association of Atlanta, 1989-92; Course Director, “Movement Disorders: An Update and Case Presentations.” Held in major U.S. cities throughout the year; sponsored by Emory University, We Move, and University of Alabama at Birmingham, 1997-Present; Visiting Professor (over 100) at: Universities throughout USA (Harvard, Duke, Stanford, U. Pennsylvania, Columbia, Washington U., U. Michigan, U. Pittsburgh, UCLA, etc.) and International Universities (U. of Lund, Sweden; Hospital Salpetriere, Paris; National Hospital for Neurology and Neurosurgery, London; University of Navarra, Pamplona, Spain; U. of Tel Aviv, Israel).

## **BOOKS**

Watts, RL, Koller WC, eds. Movement Disorders: Neurologic Principles and Practice, McGraw-Hill Publishers: New York, 1997, 779 pages.

Watts, RL, Koller WC, eds. Movement Disorders: Neurologic Principles and Practice, Second Edition, McGraw-Hill Publishers: New York, 2004, 859 pages

Watts, RL, Standaert, DG, Obeso, JA, eds, Movement Disorders: Neurologic Principles and Practice, Third Edition, McGraw-Hill Publishers: New York, 2012, 1033 pages

## **PUBLICATIONS**

1. Navar LG, PD Bell, RW White, **RL Watts**, RH Williams. Evaluation of the single nephron glomerular filtration coefficient in the dog. *Kidney Intern* 12:137- 149, 1977
2. Wiegner AW, **RL Watts**. Elastic properties of muscles measured at the elbow in man. I. Normal controls. *J Neurol Neurosurg Psychiat* 49:1171- 1176, 1986
3. **Watts RL**, Wiegner AW, Young RR. Elastic properties of muscles measured at the elbow in man. II. Patients with Parkinsonian rigidity. *J Neurol Neurosurg Psychiat* 49:1177-1181, 1986
4. Pullman S, **Watts RL**, Juncos JL, Chase TM, Sanes JN. Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. *Neurology* 38:249-254, 1988
5. **Watts RL**. Parkinson's Disease: Current understanding and future directions. *Emory Univ J Med* 2 (Apr-Jun):119-127, 1988
6. Tanner CM, **Watts RL**, Bakay RAE, KC Petruk. Adrenal medulla autografts in patients with Parkinson disease. *New Eng J Med* 321:325, 1989
7. **Watts RL**, R Dubinsky, W Koller. Objective assessment of motor disability (Chap. 2). In: Koller W, Paulson G., eds. Therapeutic Approaches in Parkinson's Disease. Marcel Dekker: New York, 1989
8. Faraj BA, Camp VM, **Watts RL**. Effect of adrenal-caudate transplantation on CSF levels of salsolinol sulfate in patients with Parkinson's disease. *J Neural Transm Suppl*. 1990; 32:481-4
9. Bakay RAE, **RL Watts**, A Freeman, PM Iuvone, N Watts, and SD Graham. Preliminary report on adrenal-brain transplantation for parkinsonism in man. *Stereotactic and Functional Neurosurgery* 54/55:312-323, 1990

10. **Watts RL**, RAE Bakay, CJ Herring, KM Sweeney, HJ Colbassani, A Mandir, LD Byrd, and PM Iuvone. Preliminary report on adrenal medullary grafting and co-grafting with sural nerve in the treatment of hemiparkinson monkeys. *Prog Brain Res* 82:581-591, 1990
11. Watts NB, RV Clark, **RL Watts**, SD Graham, and RAE Bakay. Changes in endocrine function after adrenal medullary transplantation to the central nervous system. *J Clin Endocrine Metab* 70:773-776, 1990
12. Pullman S, **RL Watts**, JL Juncos, JN Sanes. Movement amplitude choice reaction time performance in Parkinson's disease may be independent of dopaminergic status. *J Neurol Neurosurg Psych* 53:279-283, 1990
13. Greene PE, S Fahn, AE Lang, **RL Watts**, et al. What Is It? Case 1, 1990. Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb - Cortical-Basal Ganglionic Degeneration. *Movement Disorders J* 5:341-351, 1990
14. **Watts RL**, RAE Bakay, A Freeman, S Graham. Assessment of autologous adrenal-to-caudate for parkinsonism in man. *International Journal of Neurology*, 23-24:78-88, 1989-90.
15. **Watts RL**, RAE Bakay. Autologous adrenal medulla-to-caudate grafting for parkinsonism in humans and in nonhuman primates. *Frontiers in Neuroendocrinology* 12 (No. 4):357-378, 1991
16. Shults CW, DT O'Conner, A Baird, R Hill, CG Goetz, **RL Watts**, HL Klawans, PM Carvey, RAE Bakay, FH Gage, SU Hoi. Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid. *Exp Neurol* 111:276-281, 1991
17. Shoffner J, **RL Watts**, JL Juncos, A Torroni, D Wallace. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. *Ann Neurol* 30:332-339, 1991
18. Kahn N, A Freeman, JL Juncos, DE Manning, **RL Watts**. Clozapine is beneficial for psychosis in Parkinson's disease. *Neurology* 41:1699-1700, 1991
19. **Watts RL**, Mandir AS, Ahn KJ, Juncos JL, Zakers GO, Freeman A. Geriatrics. Electrophysiologic analysis of early Parkinson's disease. 1991 Aug;46 Suppl 1:31-6
20. **Watts RL**, AS Mandir, KJ Ahn, JL Juncos, GO Zakers, A Freeman. Electrophysiological Analysis of Early Parkinson's disease. *Neurology*, 41 (Suppl 2):44-49, 1991
21. Langston JW, H Widner, D Brooks, S Fahn, T Freeman, C Goetz, **RL Watts**. Core Assessment Program for Intracerebral Transplantations (CAPIT). *Movement Disorders J* 7 (No. 1):2-13, 1992

22. Wallace DC, Shoffner JM, **Watts RL**, Juncos JL, Torroni A. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. *Ann Neurol.* 1992 Jul;32(1):113-4
23. **Watts RL**, AS Mandir. Quantitative methods of evaluating Parkinson's disease. In: Olanow CW, Lieberman A (eds). Scientific Basis for the Treatment of Parkinson's Disease. Parthenon Publishing: Carnforth, 13-32, 1992
24. **Watts RL**. Parkinsonian disorders (chap.). In: Hurst JW (ed.), MEDICINE for the Practicing Physician, 3rd Edition. Butterworth-Heinemann Publishers: Stoneham, MA, 1992
25. **Watts RL**, AS Mandir. The role of motor cortex in the pathophysiology of voluntary movement deficits associated with parkinsonism. In: Cedarbaum JM, Ganche ST (eds), Neurologic Clinics of North America - Parkinson's Disease, Vol. 10 (2). W.B. Saunders Company: Philadelphia, PA, 451-469, 1992
26. Shoffner JM, MD Brown, A Torroni, MT Lott, MF Cabell, SS Mirra, MF Beal, C-C Yang, M Gearing, R Salvo, **RL Watts**, JL Juncos, LA Hansen, BJ Crain, M Fayad, CL Reckord, DC Wallace. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. *Genomics* 17, 171-184, 1993
27. Gearing M, DA Olson, **RL Watts**, SS Mirra. Progressive supranuclear palsy: neuropathological and clinical heterogeneity. *Neurology* 44, 1015-1024, 1994
28. **Watts RL**, SS Mirra, EP Richardson. Cortical-Basal Ganglionic Degeneration (Chap. 10). In: Marsden CD & Fahn S (eds). Movement Disorders 3. Butterworths: London, 282-299, 1994
29. Koller WC, Silver DE, Lieberman A, et al. (**Watts RL**). An algorithm for the management of Parkinson's disease. *Neurology* 1994; 44 (Suppl 10): S1-S52
30. **Watts RL**, SL Pullman, SL Glatt, WC Koller. Quantitative Techniques of Assessing Motor Disability. In: Koller W, Paulson G., eds. Therapy of Parkinson's Disease, 2nd ed. Marcel Dekker: New York, 47-75, 1995
31. Bliwise DL, **RL Watts**, NP Watts, DB Rye, D Irbe, ML Hughes. Nocturnal disruptive behavior in Parkinson's disease and Alzheimer's disease, *J Geriatric Psychiatry & Neurology* 8, 107-110, 1995
32. **Watts RL**, AS Mandir, RAE Bakay. Intrastratial cogafts of autologous adrenal medulla and sural nerve in MPTP-induced parkinsonian macaques: Behavioral and anatomical assessment, *Cell Transplantation* 4, 27-38, 1995
33. Goldstein FC, J Green, RM Presley, J O'Jile, A Freeman, **RL Watts**, RC Green. Cognitive estimation in patients with Alzheimer's disease. *Neuropsychiatry, Neuropsychology, Behavioral Neurology*; 9:35-42, 1996



34. Cohen-Cole SA, JL Woodard, JL Juncos, JL Kogos, EA Youngstrom, F Goldstein, **RL Watts**. Depression and disability in Parkinson's disease, *J Neuropsych & Clin Neurosci*; 8: 20-25, 1996
35. Green J, JL Woodard, BE Sirockman, GO Zakers, CL Maier, RC Green, **RL Watts**. Event-related potential P3 change in mild Parkinson's disease, *Movement Disorders J*, 11(1): 32-42, 1996
36. Parkinson Study Group\*. Effect of lazabemide on the progression of disability in early Parkinson's disease. *Ann Neurol* 40(1): 99-107, 1996. (\***Watts RL**, et al.)
37. Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, **Watts RL**. Depression and disability in Parkinson's disease. *J Neuropsychiatry Clin Neurosci*. Winter;8(1):20-5, 1996
38. Schneider JA, **Watts RL**, Gearing M, Brewer RP, Mirra SS. Corticobasal degeneration: neuropathological and clinical heterogeneity. *Neurology* 48:959-969, 1997
39. **Watts RL**. The role of dopamine agonists in early Parkinson's disease. *Neurology* 49(suppl. 1):34-48, 1997
40. **Watts RL**, Brewer RP, Schenider JA, Mirra SS. Corticobasal degeneration (Chapter 45). In: **Watts RL**, Koller WC, eds. Movement Disorders: Neurologic Principles and Practice. McGraw-Hill: New York, 611-622, 1997
41. **Watts RL**, Subramanian T, Freeman A, Goetz CG, Penn RD, Stebbins GT, Kordower JH, Bakay RAE. Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson's disease: 2 year follow-up study, *Experimental Neurology* 147:510-517, 1997
42. Subramanian T, Emerich DF, Bakay RAE, Hoffman JM, Goodman MM, Shoup TM, Miller GW, Levey AI, Hubert GW, Batchelor S, Winn SR, Saydoff JA, **Watts RL**. Polymer-encapsulated PC-12 cells demonstrate high affinity uptake of dopamine *in vitro* and <sup>18</sup>F-dopa uptake and metabolism after intracerebral implantation in nonhuman primates. *Cell Transplantation* 6(5):469-477, 1997
43. Beizer JL, Bopp JM, Kootsikis M., **Watts RL**. Mirapex (pramipexole) - New Product Bulletin. American Pharmaceutical Association, 1-16, 1997
44. Scott WK, Stajich JM, Yamaoka LH, Speer MC, Vance JM, Roses AD, Pericak-Vance MA, and the Deane Laboratory Parkinson Disease Research Group\* (\***Watts RL**, et al.). The genetic complexity of Parkinson disease, *Science* 277:387-389, 1997

45. Shannon KM, Bennett, Jr JP, Friedman JH and the Pramipexole Study Group\*. (**Watts RL**, et al.). Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease, *Neurology* 49:724-728, 1997
46. Olanow CW, Koller WC, .... **Watts RL**, Welsh MD. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. *Neurology* 50(supp. 3):S1-S57, 1998
47. Wichmann T, Bergman H, Starr PA, Subramanian T, **Watts RL**, DeLong MR. Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates. *Exp. Brain Research* 125:397-409, 1999
48. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW (in conjunction with Parkinson Epidemiology Research Committee Twin Study Clinic Centers, **Watts RL**, Emory University, Department of Neurology). Parkinson disease in Twins: An etiologic study. *JAMA* 281(4):341-346, 1999
49. Rye DB, Johnston LH, **Watts RL**, Bliwise DL. Juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness and daytime REM-onsets. *Neurology* 53:1868-1870, 1999
50. Scott WK, Yamaoka LH, Stajich JM, Scott BL, Vance JM, Roses AD, Pericak-Vance MA, and the Deane Laboratory Parkinson Disease Research Group\* (**Watts RL** et al.). The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. *Neurogenetics* 2:191-192, 1999
51. Xing D, Chen, P, Keil R, Kilts CD, Shi B, Camp VM Malveaux G, Ely T, Owens MJ, Votaw J, Davis MR, Hoffman JM, Subramanian T, Bakay RAE, **Watts RL**, Goodman MM. Synthesis, biodistribution and primate imaging of fluorine-18 labeled 2 $\beta$ -carbo-1'-fluoro-2-propoxy-3 $\beta$ -(4-chlorophenyl) tropanes: Ligands for the imaging of dopamine transporters by Positron Emission Tomography. *J Medicinal Chemistry*, 43(4): 639-648, 2000
52. Olanow WC, **Watts RL**, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment Guidelines. *Neurology* 56 (Suppl5): S1-S88, 2001
53. Koller WC, Lees A, Doder M, Hely M. (and Tolcapone vs. Pergolide Study Group: ... **Watts RL**). Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuation. *Movement Disorders*, Sept.16: 858-66, 2001
54. Distefano AL, Golbe LI, Mark M, **Watts RL**, Myers RH. Genome-wide Scan for Parkinson's disease: The GenePD Study. *Neurology*, 25: 1124-6, 2001
55. Scott WK, Nance MA, **Watts RL**, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. *JAMA*, 286:2239-44, 2001

56. Martin ER, Scott WK, Nance MA, **Watts RL**, et al . Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. *JAMA*, 286: 2245-50, 2001
57. Stover NP, **Watts RL**. Coticobasal degeneration. *Seminars in Neurology*, 21:49-58 , 2001
58. Okun MS, Stover NP, ...**Watts RL**,... DeLong MR. Complication of gamma knife surgery for Parkinson disease. *Arch Neurology* 2001; 58: 1995-2002
59. Maher NE, Golbe LI, ..., **Watts RL**, ...Myers RH. Epidemiologic Study of 203 Sibling Pairs With Parkinson's Disease: The GenePD Study. *Neurology*, 58: 79-84, 2002
60. Li Y-J, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, **Watts RL**, et al. Onset ageing neurodegenerative diseases is genetically controlled. *AM. J. Human Genetics* 2002
61. Okun MS, **Watts RL**. Depression associated with Parkinson's disease: clinical features and treatment. *Neurology*, 58 (suppl 1): 563-570, 2002
62. Distefano AL, Lew MF, ..., **Watt RL**,...Myers RH. PARK3 influences Parkinson's disease onset age: A Genome Scan in the GenePD Study. *Am J Hum Genet*, 2002
63. Subramanian T, Levey AI, Hubert GW, Miller GW, Schoepp DD, **Watts RL**. Noncompetitive AMPA glutamate receptor antagonist (LY300164) potentiates the behavioral effects of levodopa in hemiparkinsonian monkeys. *Movement Disorders*, 2002
64. Shults CW, Oakes D, Kiebertz K, Beal F, Haas R, ....**Watts, RL**. Effects of Coenzyme Q10 in Early Parkinson Disease: evidence of slowing of the functional decline. *Arch Neurol*, 1541-1550, 2002
65. Roth T, Rye DB, Borchet LD, ...**Watts RL**. Assessment of sleepiness and unintended sleep episodes in PD patients taking dopaminergic agonists. *Sleep Medicine* 4:275-280, 2003
66. Bliwise DB, Freeman A, Rye DR, **Watts RL**. Ropinirole for restless legs syndrome: A double-blind, placebo-controlled study. *Sleep Medicine*, Mar;6(2):141-147, 2003
67. Oliveira SA, **Watts RL**, Vance J. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. *Arch Neurol*, 60(7):975-80. 2003
68. Karamohamed S, **Watts RL**, et al. A haplotype at the PARK3 locus influences onset age for Parkinson Disease: The GenePD Study. *Neurology*, 61(11):1557-61, 2003
69. Whone AL, **Watts RL**, Stoessl J, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. *Annals of Neurol*, 54(1):93-101, 2003

70. van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, **Watts RL**, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. *Am J Hum Genet.* 2003 Apr;72(4):804-11. Epub Feb 28, 2003
71. van der Walt JM, Martin ER, Scott WK, Zhang F, Nance MA, **Watts RL**, Hubble JP, et al. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. *Neurology.* Apr 8;60(7):1189-91, 2003
72. Oliveira SA, Scott WK, Martin ER, Nance MA, **Watts RL**, et al. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. *Ann Neurol.* May;53(5):624-9, 2003
73. Lyons KE, Pahwa R, Comella C, **Watts RL**, et al. Benefits and risks of pharmacological treatments for essential tremor. *Drug Saf,* 26(7):461-81, 2003
74. Hoffman JM, Giroux M, Votaw JR, Kilts C, Martarello L, Votaw D, White M, Jones M, **Watts RL**, Goodman MM. Determination of Dopamine Transporter Density(DAT) in Humans with an 18F Labeled Nortropine(FECNT) and PET. *Clin Positron Imaging.* 1998 Sep;1(4):257
75. **Watts RL**, Raiser CD, Stover NP, Cornfeldt ML, Schweikert AW, Allen RC, Subramanian T, Doudet D, Honey CR, Bakay RA. Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease. *J Neural Transm Suppl.* 2003;(65):215-27
76. Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, Hauser MA, Scott WK, Small GW, Nance MA, **Watts RL**, et al. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. *Hum Mol Genet.* 2003 Dec 15;12(24):3259-67. Epub 2003 Oct 21. Erratum in: *Hum Mol Genet.* 2004 Mar 1;13(5):573
77. Sawabini KA, **Watts RL**. Treatment of depression in Parkinson's disease. *Parkinsonism Relat Disord* 2004; 10 Suppl 1:S37-41
78. Bakay RA, Raiser CD, **Watts RL**. Implantation of Spheramine in advanced Parkinson's disease. *Front Biosci* 2004;9:592-602
79. Biousse V, Skibell BC, **Watts RL**, et al. Ophthalmologic features of Parkinson's disease. *Neurology* 2004;62(2): 177-80
80. The Parkinson Group (...**Watts RL**, et al.). Levodopa and the rate of progression of Parkinson disease, the ELLDOPA study. *New England Journal of Medicine*, 2004
81. Goldman SM, Tanner CM, Olanow CW, **Watts RL**, Field RD, Langston JW. Occupations and Parkinsonism in three movement disorders clinics. *Neurology* 2005 Nov 8;65(9):1430-5

82. Olanow CW, Kieburtz K, Stern M, **Watts RL**, et al. Double-blind, Placebo-controlled Study of Entacapone in Levodopa-treated Patients with Stable Parkinson Disease. *Arch. Neurol.* 2004;61: 1563-1568
83. Sawabini KA, Juncos JL, **Watts RL**. Depression, Psychosis, and Cognitive Dysfunction in Parkinson's Disease (Chapter 11). In *Principles of Treatment in Parkinson's Disease*. London: Elsevier, 2005
84. Bliwise DL, Freeman A, Ingram CD, Rye DB, Chakravorty S, **Watts RL**. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. *Sleep Med.* 2005 Mar;6(2):141-7
85. Golbe LI, Iorio GD, Markopoulou KM, Athanassiadou A, Papapetropoulos S, **Watts RL**, et al. Glutathione S-transferase polymorphisms and onset age in a-synuclein A53T mutant Parkinson's disease. *Am J Genet B Neuropsychiatry Genet* 2006 Oct 10 [Epub ahead of print]. *Am J Med Genet B Neuropsychiatr Genet.* 2007 Mar 5;144(2):254-8
86. Stover NP, Bakay RA.E., Subramanian T, Raiser CD, Cornfeldt ML, Schweikert AW, Alan RC, **Watts RL**. Intrastratial Implantation of Human Retinal Pigment Epithelial Cells Attached to Microcarriers in Advanced Parkinson Disease. *Archives of Neurology* 2005 Dec;62(12):1833-1837
87. Elble RJ, and the Tremor Research Group and Conference Attendees (... **Watts RL**,...). Report from a US Conference on Essential Tremor, Movement Disorders, Vol. 21, No. 12, 2006, pp.:2052-2061
88. Elble RJ, Pullman SL, Matsumoto JY, Raethjen J, Deuschl G, Tintner R, and the Tremor Research Group (... **Watts RL**, ...). Tremor amplitude is logarithmically related to 4- and 5-point tremor rating scales. *Brain* 2006; 129; 2660-2666
89. Kieburtz K and the NINDS NET-PD Investigators (... **Watts RL**, ...). The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. *Neurology*, Mar 2006; 66: 664 - 671
90. Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, Golbe LI, Mark MH, Racette BA, Perlmutter JS, Parsian A, Guttman M, Nicholson G, Xu G, Wilk JB, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Suchowersky O, Labelle N, Growdon JH, Singer C, **Watts RL**, et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. *Arch Neurol.* 2006 June;63(6):826-32
91. Wilk JB, Tobin JE, Suchowersky O, Shill HA, Klein C, Wooten GF, Lew MF, Mark MH, Guttman M, **Watts RL**, et al. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. *Neurology.* 2006 Dec 26;67(12):2206-10

92. **Watts RL**, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, Blind, Controlled Trial of Transdermal Rotigotine in Early Parkinson's Disease. *Neurology* 2007; 68 (4); 272-276. (Published as Expedited Epub Jan 2007 at [www.neurology.org](http://www.neurology.org))
93. The NINDS NET-PD Investigators.\* (\***Watts RL**, et al.). A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson Disease. *Neurology* 2007;68:20-28
94. Jankovic J, **Watts RL**, Martin W, Boroojerdi B, for the SP512 Rotigotine Transdermal System Clinical Study Group. Rotigotine Transdermal System: Double-Blind, Placebo-Controlled Trial in Parkinson's Disease. *Archives of Neurology* 2007 May; 64(5):676-82
95. Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, Hunter C, Swartz JE, Elango R, Akkari PA, Leppert D, Surh L, Reeves KH, Thomas S, Ragone L, Hattori N, Pahwa R, Jankovic J, Nance M, Freeman A, Gouider-Khouja N, Kefi M, Zouari M, Ben Sassi S, Ben Yahmed S, El Euch-Fayeche G, Middleton L, Burn DJ, **Watts RL**, Henti F. Screening for LRRK2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. *Movement Disorders* 2007 Jan;22(1):55-61
96. Hauser RA, Rascol O, Korczyn AD, Stossl AJ, **Watts RL**, et al. Ten-Year Follow-up of Parkinson's Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa. *Movement Disorders J.*, 2007 Dec;22(16):2409-17
97. Stover NP, Walker HC, **Watts RL**. Corticobasal degeneration. *Handbook of Clin Neurol* 2007;84: 351-72
98. Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, Ragone L, Pahwa R, Jankovic J, Nance M, Freeman A, **Watts RL**, Hentati F. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease: *Parkinsonism Relat Disord*. 2008 Jan;14(1):77-80.
99. Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, **Watts RL**, Marson DC. Brain N-Acetylaspartate is Reduced in Parkinson Disease with Dementia: *Alzheimer Disease Associate Disorders*, 2008. Jan-Mar; 22(1): 54-60.
100. Stover NP, **Watts RL**. Spheramine for treatment of Parkinson's Disease. *Neurotherapeutics*. 2008 Apr;5(2):252-9.
101. McNicoll CF, Latourelle JC, Macdonald ME, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, **Watts RL**, et al. Huntington CAG Repeat Size Does Not Modify Onset Age in Familial Parkinson's Disease: The GenePD Study: *Movement Disorders*, 2008. April 2008, Vol. 5(2): 252-259
102. DeStefano AL, Latourelle J, Lew, MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, **Watts RL**, et al. Replication of association between *ELAVL4* AND Parkinson disease: the *GenePD* study. *Hum Genet* (2008) 124:95-99

103. Prasain, JK, ...**Watts RL**. Liquid chromatography tandem mass spectrometry identification of proanthocyanidins in rat plasma after oral administration of grape seed extract. *Phytomedicine* 2009; 16: 233-43
104. Martin RC, et al. (**Watts RL**). Medical Decision-Making Capacity in Cognitively Impaired Parkinson's Disease Patients Without Dementia. *Movement Disorders*, 2008. August 2008, Vol. 23, No. 12, pp. 1867-1874
105. Pankratz N, et al. (**Watts RL**). Genomewide association study for susceptibility genes contributing to familial Parkinson disease. *Hum Genet* 2008; 10.1007/s00439-00439-008-0582-9
106. The NINDS NET-PD Investigators.\* (**Watts RL**, et al.). A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. *Clin Neuropharmacol*. 2008 May-Jun;31(3):141-50
107. Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, **Watts RL**, Marson DC. Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. *Alzheimers Dement*. 2008 Nov;4(6):421-7
108. Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, **Watts RL**, et al. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. *BMC Med*. 2008 Nov 5;6:32
109. Walker HC, Lyerly MJ, Cutter GR, Hagood J, Stover, NP, Guthrie, SL, Guthrie BL, **Watts, RL**. Weight changes associated with unilateral STN DBS and advanced PD. *Parkinsonism Relat Disord*. 2009;15:709-11
110. Walker HC, Guthrie SL, Wang DL, **Watts RL**, and Guthrie BL. Bilateral effects of unilateral subthalamic deep brain stimulation on Parkinson disease at 1 year. *Neurosurgery*. 2009 Aug;65(2):302-9; discussion 309-10
111. Walker HC, Boswell DB, Phillips DB, Guthrie SL, Guthrie BL, Montgomery EB, **Watts RL**. Relief of acquired stuttering associated with Parkinson disease by unilateral left subthalamic brain stimulation. *J of Speech, Language, and Hearing Research*. 2009;52: 1652-7
112. Walker HC, Dure LS, **Watts RL**. *Movement and Balance Disorders. Pediatric Practice: Neurology*. Eds. Carney P and Guyer J. 2009
113. Shenai MB, Walker H, Guthrie S, **Watts R**, Guthrie BL. Construction of relational topographies from the quantitative measurements of functional deep brain stimulation using a 'roving window' interpolation algorithm. *Stereotact Funct Neurosurg* 2010;88: 16-23

114. Sethi K, Factor S, **Watts RL**. Quality of life in Parkinson's disease patients following adjunctive tolcapone therapy: Results of an open-label, multicenter, community-based trial. *CNS Spectr* 2010 Jan; (15) 27-32
115. **Watts RL**, Lyons KE, et al. Outset of Dyskinesia With Adjunct Ropinirole Prolonged Release or Additional Levodopa in Early Parkinson's Disease. *Mov Disord* 2010 May 15; 25(7) 858-66
116. Coa X, Yasuda T, Uthayathas S, **Watts RL**, Mouradian MM, Mochizuki H, Papa SM. Striatal overexpression of  $\Delta$ FosB reproduces involuntary movements developed after chronic levodopa treatment. *J Neurosci* 2010 May 26; 30(21) 7335-43
117. Factor S, Mark MH, Gross R, **Watts RL**, et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. *Parkinsonism Relat Disord*. 2010 Jul;16(6):423-6. Epub 2010 Mar 24
118. Walker HC, **Watts RL**, Schrandt CJ, Huang H, Guthrie SL, Guthrie BL, Montgomery EB. Activation of subthalamic neurons by contralateral subthalamic deep brain stimulation in Parkinson disease. *J Neurophysiol*. 2011 Mar; 105(3):112-21. Epub 2010 Dec 22
119. Gross RE, **Watts RL**, Hauser RA, et al. Double-blind, randomized, sham-surgery-controlled study to evaluate the safety, tolerability, and efficacy of bilateral intrastriatal Spheramine® implantation in patients with advanced Parkinson's disease. *Lancet Neurology*, 2011 Jun; 10(6):509-19. Epub 2011 May 2011
120. Amara AW, Standaert G... **Watts RL**, et al. Unilateral STN DBS improves subjective sleep quality in Parkinson's disease. *Parkinsonism Relat Disord*. 2012 Jan;18(1):63-8. Epub 2011 Sep 15
121. Elble R, Comella C, Fahn S, **Watts RL**, et al. Validity and reliability of a new scale for essential tremor. *Movement Disorders* 2012 (in press)
122. Walker HC, Huang H, Gonzalez CL... **Watts RL**, et al. Short latency activation of cortex by clinically effective thalamic brain stimulation for tremor. *Mov Disord*. 2012 Aug 27. Doi; 10.1002/mds.25137. [Epub ahead print]
123. Aldewereld Z, Huang H, **Watts RL**, Montgomery E. Effects of Deep Brain Stimulation (DBS) on M-waves in Parkinson's disease: evidence of increased synchronization. *Movement Disorders* 2012 (submitted)
124. Martin RC, Triebel K, Nicholas A, Stover N,... **Watts RL**, et al. Impaired financial abilities in Parkinson's Disease patients with mild cognitive impairment and dementia. 2012 (under review)



125. Martin RC, Triebel K, Nicholas A, Stover N, ... **Watts RL**, et al. Impairment in Parkinson's Disease Patients with Mild Cognitive Impairment and Dementia. *Parkinsonism & Related Disorders*. 2013
126. Sung VW, **Watts RL**, Schrandt CJ, Guthrie S, Wang D, Amara AW, Guthrie BL, Walker HC. Clinical phenotype predicts early staged bilateral deep brain stimulation in Parkinson's disease. Clinical article. *Journal of Neurosurgery* August 2013
127. Huang He, **Watts RL**, Montgomery, EB. Effects of Deep Brain Stimulation Frequency on Bradykinesia of Parkinson's Disease. *Movement Disorders*. 2013
128. Kelly N, Ford M, Standaert D, **Watts RL**, Williams J, Lieb L, et al. Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's Disease. *Journal of Applied Physiology*. 2014.